# Trophos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trophos

- Industry: Pharmaceuticals
- Headquarters: Marseille, France
- Website: www.trophos.com
- Total disclosed funding: $19M
- Latest round: Series C (Sep 4, 2007)
- Investors on record: 4

## About

Trophos is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS).Founded in 1999 in Marseille, France, Trophos specializes in biopharmaceuticals targeting neurodegenerative diseases. In January 2015, Roche Holding agreed to acquire Trophos for EUR 470.000 mn, marking a significant shift in the company's trajectory after a previous acquisition option by Actelion in 2010 was not exercised. The company has engaged in three total deals, with the most recent occurring on January 16, 2015. The founder's details are currently unavailable.Trophos focuses on developing innovative therapies for neurodegenerative conditions, including a significant emphasis on treatments for ALS. Their product pipeline seeks to address critical needs in this therapeutic area by utilizing advanced scientific research and clinical data to innovate treatment solutions.In 2015, Trophos reported a revenue of EUR 3.28 mn. The company’s revenue generation model relies on the sales of its therapeutic products targeting specific conditions, though specific details on partnerships or pricing strategies are currently not provided.Trophos plans to leverage recent funding from Roche Holding to support the development of new therapies in neurodegenerative diseases. Following the acquisition deal in January 2015, the company aims to enhance its R&D capabilities and expand its presence in international markets to facilitate the launch of its product pipeline focused on ALS and similar disorders.

## Funding rounds

- Series C, Sep 4, 2007, $12M — SGAM Private Equity, Turenne Groupe, Smalt Capital, APICAP
- Series B, Apr 1, 2003, $7M — SGAM Private Equity, Turenne Groupe, Smalt Capital

## Investors

- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series B, Series C
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B, Series C
- Smalt Capital (https://capitalatlas.ai/funds/smalt-capital) — Series B, Series C
- APICAP (https://capitalatlas.ai/funds/apicap) — Series C